Doxorubicin conjugates: a practical approach for its cardiotoxicity alleviation
Date
2024-04-21Author
Ibrahim, Abed AlqaderNsairat, Hamdi
Al-Sulaibi, Mazen
El-Tanani, Mohamed
Jaber, Areej M.
Lafi, Zainab
Barakat, Rahmeh
Abuarqoub, Duaa Azmi
Mahmoud, Ismail Sami
Obare, Sherine O.
Aljabali, Alaa A.A.
Alkilany, Alaaldin M.
Alshaer, Walhan
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Introduction: Doxorubicin (DOX) emerges as a cornerstone in the arsenal of potent chemotherapeutic agents. Yet, the clinical deployment of DOX is tarnished by its proclivity to induce severe cardiotoxic effects, culminating in heart failure and other consequential morbidities. In response, a panoply of strategies has undergone rigorous exploration over recent decades, all aimed at attenuating DOX’s cardiotoxic impact. The advent of encapsulating DOX within lipidic or polymeric nanocarriers has yielded a dual triumph, augmenting DOX’s therapeutic efficacy while mitigating its deleterious side effects. Areas covered: Recent strides have spotlighted the emergence of DOX conjugates as particularly auspicious avenues for ameliorating DOX-induced cardiotoxicity. These conjugates entail the fusion of DOX through physical or chemical bonds with diminutive natural or synthetic moieties, polymers, biomolecules, and nanoparticles. This spectrum encompasses interventions that impinge upon DOX’s cardiotoxic mechanism, modulate cellular uptake and localization, confer antioxidative properties, or refine cellular targeting. Expert opinion: The endorsement of DOX conjugates as a compelling stratagem to mitigate DOX-induced cardiotoxicity resounds from this exegesis, amplifying safety margins and the therapeutic profile of this venerated chemotherapeutic agent. Within this ambit, DOX conjugates stand as a beacon of promise in the perpetual pursuit of refining chemotherapy-induced cardiac compromise.
Collections
- Pharmacy Research [1316 items ]